Pemetrexed (ALIMTA), A Novel Multitargeted Antineoplastic Agent

@article{Adjei2004PemetrexedA,
  title={Pemetrexed (ALIMTA), A Novel Multitargeted Antineoplastic Agent},
  author={A. Adjei},
  journal={Clinical Cancer Research},
  year={2004},
  volume={10},
  pages={4276s - 4280s}
}
  • A. Adjei
  • Published 2004
  • Biology, Medicine
  • Clinical Cancer Research
  • Pemetrexed (ALIMTA, LY231514, MTA) is a novel antimetabolite that inhibits at least three enzymes involved in the folate pathway. These enzymes are thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Pemetrexed has demonstrated clinical activity in non-small cell lung cancer as well as in a broad array of other solid tumors, including mesothelioma, breast, colorectal, bladder, cervical, gastric and pancreatic cancer. In non-small cell lung cancer… CONTINUE READING
    Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications
    • 209
    • PDF
    Clinical studies of pemetrexed and gemcitabine combinations.
    • 14
    Molecular mechanism implicated in Pemetrexed-induced apoptosis in human melanoma cells
    • 28
    Emerging role of pemetrexed in ovarian cancer
    • 13